NAMS

SEC Form PRE 14A filed by NewAmsterdam Pharma Company N.V.

Truist initiated coverage on NewAmsterdam Pharma with a new price target

Director Lange Louis G sold $1,357,230 worth of Ordinary Shares (44,619 units at $30.42), decreasing direct ownership by 81% to 10,360 units (SEC Form 4)

SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

Director Lange Louis G sold $828,950 worth of Ordinary Shares (28,186 units at $29.41) and exercised 44,619 in-the-money units of Ordinary Shares at a strike of $11.50, increasing direct ownership by 431% to 54,979 units (SEC Form 4)

Chief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 300,000 units of Ordinary Shares and sold $9,090,868 worth of Ordinary Shares (300,000 units at $30.30) (SEC Form 4)

SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

Chief Executive Officer Davidson Michael H. converted options into 443,707 units of Ordinary Shares and sold $14,753,258 worth of Ordinary Shares (443,707 units at $33.25) (SEC Form 4)

SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Chief Scientific Officer Kastelein Johannes Jacob Pieter sold $1,605,998 worth of Ordinary Shares (45,481 units at $35.31), decreasing direct ownership by 46% to 53,500 units (SEC Form 4)

SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

SEC Form S-8 filed by NewAmsterdam Pharma Company N.V.

SEC Form 10-K filed by NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.

SEC Form SCHEDULE 13G filed by NewAmsterdam Pharma Company N.V.

Chief Accounting Officer Kooij Louise Frederika exercised 72,428 units of Ordinary Shares at a strike of $10.90 and sold $2,335,860 worth of Ordinary Shares (72,428 units at $32.25) (SEC Form 4)

Chief Accounting Officer Kooij Louise Frederika sold $2,415,843 worth of Ordinary Shares (72,572 units at $33.29) and exercised 72,572 units of Ordinary Shares at a strike of $10.90 (SEC Form 4)

Chief Financial Officer Somaiya Mayur Ian exercised 100,000 units of Ordinary Shares at a strike of $9.26 and sold $3,260,618 worth of Ordinary Shares (100,000 units at $32.61) (SEC Form 4)

SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

Director Van Der Kamp Hilde Johanna was granted 3,400 units of Ordinary Shares, increasing direct ownership by 49% to 10,360 units (SEC Form 4)

Director Gulfo Adele M. was granted 3,400 units of Ordinary Shares, increasing direct ownership by 31% to 14,260 units (SEC Form 4)

Chief Executive Officer Davidson Michael H. sold 11,582 units of Ordinary Shares and was granted 81,000 units of Ordinary Shares, increasing direct ownership by 18% to 459,859 units (SEC Form 4)

Director Lewis William was granted 3,400 units of Ordinary Shares, increasing direct ownership by 49% to 10,360 units (SEC Form 4)